Pierre Lescuyer
Overview
Explore the profile of Pierre Lescuyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1085
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raptis C, Berger C, Ciurea A, Andrey D, Polysopoulos C, Lescuyer P, et al.
Front Immunol
. 2022 Oct;
13:1016927.
PMID: 36311791
Patients with inflammatory rheumatic diseases (IRD) are at increased risk for worse COVID-19 outcomes. Identifying whether mRNA vaccines differ in immunogenicity and examining the effects of immunomodulatory treatments may support...
2.
Steiner C, Lescuyer P, Cutler P, Tille J, Ducret A
Mol Cell Proteomics
. 2022 Sep;
21(11):100416.
PMID: 36152753
The identification of clinically relevant biomarkers represents an important challenge in oncology. This problem can be addressed with biomarker discovery and verification studies performed directly in tumor samples using formalin-fixed...
3.
Smit C, Sen S, von Dach E, Karmime A, Lescuyer P, Tonoli D, et al.
Antibiotics (Basel)
. 2022 Sep;
11(9).
PMID: 36139969
Current dose reductions recommended for amoxicillin in patients with impaired kidney function could lead to suboptimal treatments. In a prospective, observational study in hospitalized adults with varying kidney function treated...
4.
Royston L, Masouridi-Levrat S, Gotta V, Royston E, Pressacco-Brossier C, Abi Aad Y, et al.
Antimicrob Agents Chemother
. 2022 Jul;
66(8):e0065722.
PMID: 35876579
With balanced safety-efficacy profile, letermovir anti-cytomegalovirus (CMV) prophylaxis is used in hematopoietic stem cell transplant recipients (HSCTR). We assessed feasibility and usefulness of letermovir therapeutic drug monitoring (TDM) in HSCTR....
5.
Marti C, Stirnemann J, Lescuyer P, Tonoli D, von Dach E, Huttner A
Int J Antimicrob Agents
. 2022 May;
59(6):106601.
PMID: 35533793
Therapeutic drug monitoring (TDM) of β-lactam antibiotics is increasingly used to overcome rising antimicrobial resistance and improve antibiotic exposure. However, there is little guidance on target amoxicillin plasma concentrations. We...
6.
Visconti G, Olesti E, Gonzalez-Ruiz V, Glauser G, Tonoli D, Lescuyer P, et al.
Talanta
. 2022 Mar;
:123288.
PMID: 35304010
No abstract available.
7.
Tagliente N, Lescuyer P, Moreau V, Collet T, Genton L
Rev Med Suisse
. 2022 Mar;
18(772):445-452.
PMID: 35266345
Since their discovery more than a century ago to this day, vitamins went from misunderstood molecules with mysterious properties to fundamental components with undoubted clinical implications. Despite the scientific progresses...
8.
Nguyen A, Finci L, Berney T, Tonoli D, Lescuyer P, Jayo M, et al.
Clin Transplant
. 2022 Mar;
36(5):e14624.
PMID: 35235221
No abstract available.
9.
Visconti G, Olesti E, Gonzalez-Ruiz V, Glauser G, Tonoli D, Lescuyer P, et al.
Talanta
. 2021 Dec;
240:123149.
PMID: 34954616
The use of mass spectrometry methods with triple quadrupole instruments is well established for quantification. However, the preparation of calibration curves can be time-consuming and prone to analytical errors. In...
10.
Piletta-Zanin A, De Mul A, Rock N, Lescuyer P, Samer C, Rodieux F
Front Pharmacol
. 2021 Sep;
12:717148.
PMID: 34483924
Tacrolimus is a calcineurin inhibitor characterized by a narrow therapeutic index and high intra- and inter-individual pharmacokinetic variability. Therapeutic drug monitoring in whole-blood is the standard monitoring procedure. However, tacrolimus...